SeqOne Genomics

Executive Summary

SeqOne Genomics is a French bioinformatics company offering an all-in-one, AI-powered genomic analysis platform for clinical and research laboratories. Its sequencer-agnostic software streamlines interpretation of next-generation sequencing (NGS) data across germline, somatic, and infectious disease applications, and is compliant with IVDR CE-IVD Class C standards. Founded in 2017 and headquartered in Montpellier, France, the company addresses the growing need for scalable, accurate, and regulatory-ready genomic interpretation tools in precision medicine. The platform’s ability to handle diverse NGS workflows positions SeqOne to capture share in the rapidly expanding clinical genomics market, driven by increasing adoption of NGS in oncology and rare disease diagnostics. While the company has not publicly disclosed funding or valuation, its cloud-based, regulatory-compliant solution likely appeals to hospital networks and diagnostic labs seeking to streamline operations. Future growth will depend on expanding its CE-IVD portfolio, forging strategic partnerships with sequencer vendors or pharmaceutical firms, and securing additional capital to scale commercial efforts.

Upcoming Catalysts (preview)

• Q3 2026Expansion of CE-IVD marking to additional clinical panels (e.g., somatic oncology)75% success
• Q4 2026Strategic partnership with a major sequencing platform provider or pharmaceutical company60% success
• H1 2027Series B or C funding round to accelerate commercial expansion80% success